Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2017-06-01
Schriftenreihe:	Blood Advances
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!